Pfizer Takes 3% Stake In Sosei On Back Of Heptares GPCR Deal

Heptares Therapeutics, a Sosei Group subsidiary, has entered a deal to apply its drug discovery technology to 10 G protein-coupled receptor (GPCR) targets selected by Pfizer Inc. across a number therapeutic areas. The deal also sees Pfizer acquiring a 3% equity stake in Sosei.

Heptares Therapeutics, a Sosei Group subsidiary, has entered a deal to apply its drug discovery technology to 10 G protein-coupled receptor (GPCR) targets selected by Pfizer Inc. across a number therapeutic areas. The deal also sees Pfizer acquiring a 3% equity stake in Sosei.

Heptares will receive an undisclosed upfront payment and potentially $189m in milestone payments per target, plus potential royalties on product...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By 

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

More from Therapy Areas

In Brief: Nanoscope Ploughs Forward With FDA Application For Retinitis Pigmentosa Gene Therapy

 
• By 

Nanoscope’s experimental gene therapy, MCO-010, is designed to target the broader retinitis pigmentosa population, regardless of the underlying gene mutation, with a completed US regulatory submission expected in early 2026.

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By 

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.